Abbott Laboratories confirms CE mark for dual sensor, shares in S&P 500 healthcare focus

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 22:26.

Abbott Laboratories (US0028241000) has obtained a CE mark in the European Union for what it describes as the world’s first dual glucose-ketone sensing technology for people living with diabetes, according to a company communication referenced in market overviews. A German market snapshot on finanzen100 highlights the approval and situates the company within the S&P 500.

What the CE mark covers

The new system is positioned as a continuous sensor capable of tracking both blood glucose and ketone levels, expanding on Abbott’s established FreeStyle Libre glucose monitoring franchise for diabetes patients. The company’s own product pages describe a broader portfolio in continuous glucose monitoring and cardiometabolic diagnostics.

According to the German quotation page, the CE mark was communicated around June 22 and framed as a world-first for dual glucose-ketone sensing, underscoring Abbott’s attempt to differentiate its diabetes technology versus global peers such as Dexcom and Medtronic in the diagnostics space. The same source lists Abbott alongside other S&P 500 healthcare constituents.

Tuesday focus on strategy and operations

Abbott is listed on the NYSE under ticker ABT and is part of the S&P 500, with operations spanning diagnostics, medical devices, nutrition, and branded generics across more than 160 countries. A recent profile on Bitget summarizes Abbott’s listing on the NYSE and its status as a medical specialties company.

For 2024, Abbott reported adjusted diluted earnings per share of 4.67 US dollars, which the same profile notes was at the upper end of the company’s guidance range, indicating consistent execution across its diversified healthcare portfolio. The analysis emphasizes the contribution from its medical devices and diagnostics businesses.

The diabetes technology behind the stock

Abbott’s diabetes care business has been built around its FreeStyle Libre portfolio, a family of wearable sensors and readers designed to provide near real-time glucose data without routine finger-stick testing. The company’s product information highlights multiple Libre generations with differing wear durations.

Where Abbott shares trade today

Abbott Laboratories shares (US0028241000) trade on the NYSE under ticker ABT, and the last available consolidated quote for June 22, 2026 shows 87.78 US dollars as the official close, with 88.34 US dollars reported in extended trading as of 08:05 Eastern time the following session. MarketBeat lists the closing and extended trade data for ABT

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Neither the author nor ad-hoc-news.de assumes any liability for decisions made based on this text.